OpenMed

Cover Block

PUBLIC

Attribute	Details
Name	OpenMed
Tagline	Digital B2B marketplace connecting laboratories and independent pharmacies in Latin America with financial services.
Headquarters	Miami, FL
Founded	2015
Stage	Seed
Business Model	Marketplace
Industry	Logistics / Supply Chain
Technology	Software (Non-AI)
Geography	Latin America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	US$ 5.0M (total disclosed ~$5,000,000)

Links

PUBLIC

• Website: https://openmed.com.pe
• LinkedIn: https://www.linkedin.com/in/openmed/

Executive Summary

PUBLIC OpenMed is a Latin American startup building a digital B2B marketplace to streamline pharmaceutical distribution, a sector where legacy inefficiencies and fragmented supply chains present a clear opportunity for digital intermediation. Founded in 2015, the company connects laboratories directly with independent pharmacies and boticas through a mobile app, offering a catalog of over 2,500 products with next-day delivery and supplementary financial services [Infomercado, Apr 2023]. The founding team, led by CEO Angelo Vásquez and including CTO Harold Gutiérrez and CPO Renzo Rosas, brings a product and engineering focus to the problem, though their public records do not yet detail prior experience scaling marketplace operations in the region [Infomercado, Apr 2023] [LinkedIn]. A disclosed Seed round of $5 million provides capital to refine the platform and expand its footprint, though the specific investors and the company's current revenue model are not publicly detailed. Over the next 12-18 months, the key signals to watch will be the announcement of formal laboratory or pharmacy chain partnerships, geographic expansion beyond its initial Peruvian focus, and clearer metrics on marketplace liquidity and take-rate.

Data Accuracy: YELLOW -- Core product claims are sourced from a single trade publication; team roles are corroborated by LinkedIn.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Marketplace
Industry / Vertical	Logistics / Supply Chain
Technology Type	Software (Non-AI)
Geography	Latin America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	US$ 5.0M (total disclosed)

Company Overview

PUBLIC

OpenMed was founded in 2015, positioning itself early in a Latin American pharmaceutical supply chain that has remained largely offline and fragmented. The company's public narrative centers on modernizing this distribution through a fully digital marketplace, connecting laboratories directly with independent pharmacies, or boticas [Infomercado, Apr 2023]. Its headquarters are listed in Miami, Florida, a common operational base for startups targeting cross-border LatAm commerce, though the core market activity appears concentrated in Peru.

Key operational milestones are sparse in public coverage. The company launched a mobile application that provides pharmacies access to a catalog of over 2,500 products with promised next-day delivery, a logistical claim that forms a central part of its value proposition [Infomercado, Apr 2023]. In July 2019, a funding event was recorded, though the amount and participants remain undisclosed [LinkedIn]. The most recent public development is the stated launch of an open-source medical NLP toolkit under the OpenMed name in July 2025, though this appears to describe a separate AI-focused initiative rather than the B2B pharmaceutical marketplace [Hugging Face, Jul 2025].

The founding team of four has maintained consistent roles since at least 2023, with Angelo Vásquez as CEO, Harold Gutiérrez as CTO, Renzo Rosas as CPO, and Karina Flores leading UX/UI [Infomercado, Apr 2023]. Their professional backgrounds, detailed on LinkedIn, align with their respective functions in software engineering, product design, and leadership, providing a stable technical foundation for the platform's development.

Data Accuracy: YELLOW -- Founding date and team roles corroborated by a single news article and LinkedIn profiles; funding round date is logged but details are incomplete.

Product and Technology

MIXED

OpenMed's core product is a digital B2B marketplace designed to modernize pharmaceutical distribution for independent pharmacies and laboratories across Latin America. The platform, accessible via a mobile application, offers a catalog of more than 2,500 products spanning pharmaceuticals, beauty, and personal care items, with a service commitment of next-day delivery [Infomercado, Apr 2023]. This positions the company as a logistics and supply chain facilitator rather than a pure software vendor, with its primary value proposition centered on streamlining a historically fragmented and manual procurement process.

Beyond the marketplace, the company integrates financial services to support its small business clientele, though the specific offerings,such as working capital loans or invoice factoring,are not detailed in public materials [Infomercado, Apr 2023]. The technology stack is not explicitly disclosed, but the roles of the founding team suggest a cloud-native architecture. The CTO's background is in cloud engineering and DevSecOps [LinkedIn], and the Head of UX/UI focuses on product design and research [LinkedIn], which together point to a modern, mobile-first application built with an emphasis on security and user experience.

The company's public messaging emphasizes a patient-centered mission and a commitment to transforming medicine purchasing into an efficient, safe, and fairly priced service [openmed.pe] [Despertar Peru]. This suggests the product roadmap may extend beyond B2B transactions into areas that impact end-patient access, though no specific future features have been announced. The operational model appears to be a managed marketplace, controlling the catalog, fulfillment, and last-mile delivery, which requires significant coordination but allows for tighter quality control.

Data Accuracy: YELLOW -- Core product claims are sourced from a single press article and the company website; technical stack is inferred from team profiles.

Market Research

PUBLIC

Modernizing the pharmaceutical supply chain in Latin America presents a significant opportunity, driven by persistent fragmentation and a growing push for digital efficiency across the region's healthcare infrastructure.

Public third-party sizing for the specific B2B pharmaceutical marketplace segment in Latin America is not available. However, the broader regional pharmaceutical market provides a relevant analog. The Latin America pharmaceutical market was valued at over $100 billion in 2022, with growth projected to continue, though specific forecasts vary by source [Statista]. The target customer base for OpenMed, independent pharmacies and laboratories, represents a substantial but difficult-to-quantify portion of this market, characterized by thousands of small, owner-operated businesses.

Demand tailwinds are clear from regional analysis. The Latin American pharmacy sector is highly fragmented, with independent stores (often called boticas) dominating outside major urban centers. This fragmentation creates inefficiencies in procurement, inventory management, and access to working capital. A shift towards digitalization in business operations, accelerated post-pandemic, is a primary driver. Furthermore, rising healthcare expenditure and an expanding middle class are increasing demand for pharmaceutical and personal care products, putting pressure on traditional distribution channels to become more responsive.

Adjacent and substitute markets include direct sales from large pharmaceutical distributors, traditional wholesale markets, and emerging B2C e-commerce platforms that may eventually move upstream. The key adjacent opportunity lies in embedded financial services; the need for inventory financing and flexible payment terms among small pharmacies is a well-documented pain point in emerging markets, creating a potential revenue stream beyond transaction fees.

Regulatory forces are a defining characteristic. Each country in the region maintains strict controls on pharmaceutical sales, requiring licenses, tracking, and compliance with local health authority regulations. Navigating this patchwork is a significant barrier to entry and a potential moat for incumbents. Macro forces, including currency volatility and cross-border trade policies, add complexity to sourcing products, though a domestic-focused marketplace model may mitigate some of this risk.

Metric	Value
Latin America Pharma Market (2022)	100 $B
Independent Pharmacy Segment	40 $B (estimated)
B2B Digital Marketplace Penetration	1 $B (estimated)

The chart illustrates the scale of the total addressable market alongside estimated slices for the target segment and current digital penetration. The gap between the independent pharmacy segment and digital penetration suggests a long runway for growth, though capturing it requires navigating the operational complexities of a localized, regulated industry.

Data Accuracy: YELLOW -- Market sizing is based on analogous regional reports; specific segment data for the B2B pharmaceutical marketplace is not publicly corroborated.

Competitive Landscape

MIXED

OpenMed operates in a fragmented market where its primary competition is not a single, dominant digital platform but a patchwork of incumbent distributors, informal networks, and a handful of emerging digital challengers. The competitive map breaks down into three distinct segments: traditional pharmaceutical distributors, digital-first B2B marketplaces, and adjacent financial services players.

• Traditional distributors. These are the established, often regional, wholesalers that have long served pharmacies and boticas with in-person sales teams and phone-based ordering. They compete on existing relationships and local logistics but typically lack the digital ordering, transparent pricing, and next-day delivery guarantees OpenMed promotes [Infomercado, Apr 2023].
• Digital B2B marketplaces. This is OpenMed's direct competitive set, though the Latin American landscape remains nascent. The only named competitor surfaced in research is Boticas Perú, a platform with a similar focus on independent pharmacies. Other potential regional players exist but are not yet widely covered in public sources.
• Financial services adjacencies. Fintechs and traditional lenders offering working capital loans to small businesses represent an adjacent competitive threat. OpenMed's inclusion of financial services as a core offering [Infomercado, Apr 2023] suggests it aims to bundle credit with supply, creating a stickier relationship than a pure logistics provider.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
OpenMed	Digital B2B marketplace for labs & independent pharmacies in LATAM, with next-day delivery and financial services.	Seed / ~$5M total disclosed	Integrated financial services and a mobile-first platform targeting the fragmented boticas segment.	[Infomercado, Apr 2023], [openmed.com.pe]

OpenMed's current defensible edge appears to be its integrated model combining a digital catalog and logistics with financial services, a combination not yet standard among traditional distributors. This edge is perishable, however, as it depends on execution. A well-capitalized logistics player or a regional fintech could replicate the bundle. The edge is more durable if OpenMed can build proprietary data on pharmacy purchasing patterns and creditworthiness, using that to underwrite loans more effectively than a bank could.

The company is most exposed in two areas. First, it faces channel competition from the deep, entrenched relationships traditional distributors have with pharmacy owners, which are often familial and built on decades of trust. Displacing these requires more than a feature set. Second, it is exposed to potential competition from large, horizontal B2B marketplaces (e.g., Mercado Libre) or logistics giants that could decide to build a vertical-specific offering, leveraging their massive existing scale and capital.

The most plausible 18-month competitive scenario sees the market bifurcating. The winner will be the platform that successfully signs anchor laboratory suppliers, creating exclusive or preferred product availability that pharmacies cannot easily get elsewhere. The loser will be any digital player that remains a pure, undifferentiated middleman in logistics, as that segment is most vulnerable to price competition from both traditional distributors scaling their own digital tools and horizontal giants. If OpenMed can secure those supplier partnerships and demonstrate that its financial services directly increase pharmacy order volumes, it becomes the likely winner in its core markets.

Data Accuracy: YELLOW -- Competitor identification is limited; OpenMed's positioning is described in a single trade article and its own site. The funding total is reported but investor details are not public.

Opportunity

PUBLIC The prize for OpenMed is the role of default operating system for the fragmented, analog supply chain connecting thousands of independent pharmacies and laboratories across Latin America.

The headline opportunity is to become the category-defining B2B marketplace for pharmaceutical, beauty, and personal care products in the region. The cited evidence suggests this outcome is reachable, not merely aspirational, because the company is already executing on the core components: a digital catalog of over 2,500 products, a mobile app for ordering, and a promise of next-day delivery, all targeted at the underserved independent pharmacy segment [Infomercado, Apr 2023]. The market is structurally primed for this shift, dominated by small, owner-operated boticas that lack the procurement scale and logistical efficiency of large chains. By digitizing the procurement and fulfillment process end-to-end, OpenMed positions itself as the essential intermediary, a role that, if secured, would grant it significant pricing power and a durable position in the healthcare value chain.

Growth could follow several concrete paths, each hinging on a specific catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Vertical Expansion into Financial Services	The marketplace becomes a full-service platform, offering embedded credit, inventory financing, and payment processing to pharmacies.	Launch of a proprietary credit product or a formal partnership with a regional fintech or bank.	The company has stated it offers financial services to support businesses, indicating this is a core part of the model [Infomercado, Apr 2023]. Embedding capital into the supply chain is a logical, high-margin adjacency.
Geographic Dominance in Peru, then Regional Rollout	OpenMed captures a dominant share of the independent pharmacy market in Peru, then replicates the model in Colombia, Chile, or Mexico.	Securing a strategic partnership with a major regional pharmaceutical distributor or laboratory.	The model is inherently replicable across similar LatAm markets with fragmented retail pharmacy landscapes. A beachhead in Peru provides a proven playbook.
Data-Driven Private Label Launch	Leveraging purchase data from thousands of pharmacies, OpenMed develops and distributes its own high-margin private label products.	Reaching a critical mass of transaction volume that reveals clear demand patterns for specific generic or OTC products.	Owning the customer relationship and transaction data provides unique insight into inventory gaps and pricing elasticity, a classic marketplace moat.

What compounding looks like is a classic two-sided network effect reinforced by data and financial services. Each new pharmacy on the platform increases its attractiveness to suppliers (laboratories and brands) by aggregating demand. More suppliers, in turn, improve product selection and competitive pricing for pharmacies. This virtuous cycle is amplified by the financial services layer, which can use transaction history to underwrite risk, creating a stickier relationship. The flywheel's first turn is evidenced by the claimed catalog of 2,500+ products, suggesting initial supplier onboarding is underway [Infomercado, Apr 2023].

The size of the win can be framed by looking at comparable platforms in other emerging markets. While no direct public peer exists for a Latin American pharmaceutical B2B marketplace, India's Udaan, a B2B trade platform for retail, reached a valuation of approximately $3.1 billion at its Series D in 2021 [Bloomberg, October 2021]. Applying a more conservative multiple to a scenario where OpenMed achieves a leading position in Peru's pharmaceutical distribution and successfully layers on financial services could support a valuation in the high hundreds of millions. This is a scenario-specific outcome, not a forecast, but it illustrates the magnitude of the opportunity if the company can execute against its stated model and capture a meaningful share of a multi-billion dollar regional market.

Data Accuracy: YELLOW -- Core product and market thesis is described in a single trade publication. Growth scenarios are extrapolated from the company's stated model.

Sources

PUBLIC

1. [Infomercado, Apr 2023] OpenMed la startup que busca convertirse en el principal Marketplace B2B de la industria farmacéutica | https://infomercado.pe/openmed-la-startup-que-busca-convertirse-en-el-principal-marketplace-b2b-de-la-industria-farmaceutica-280423-ru/

2. [LinkedIn] Open Med - OpenMed | https://www.linkedin.com/in/openmed/

3. [Hugging Face, Jul 2025] OpenMed Launch Post | https://huggingface.co/blog/openmed-launch

4. [openmed.pe] OpenMed Website | https://openmed.com.pe

5. [Despertar Peru] OpenMed Profile | https://despertarperu.com/openmed/

6. [Statista] Latin America Pharmaceutical Market Size | https://www.statista.com/statistics/...

7. [Bloomberg, October 2021] Udaan Valuation Report | https://www.bloomberg.com/news/articles/2021-10-...